Two Novel Mutations in the First Transmembrane Domain of Presenilin1 Cause Young-Onset Alzheimer's Disease.

BACKGROUND The presenilin-1 protein (PS1) is the catalytic unit of γ-secretase implicated in the production of abnormally long forms of amyloid-β (Aβ), including Aβ42, proteins thought critical in the pathogenesis of Alzheimer's disease (AD). In AD of autosomal dominant inheritance, the majority of pathogenic mutations have been found in the PSEN1 gene within which the location of the mutation can provide clues as to the mechanism of pathogenesis. OBJECTIVE To describe clinical features of two novel mutations in the transmembrane portion 1 (TMD-1) of PSEN1 as well as biochemical features in one and neuropathological findings in the other. METHODS Two index patients with young onset AD with an autosomal dominant pattern of inheritance underwent clinical and imaging assessments, as well as PSEN1 sequencing. Postmortem examination was completed in one patient. An artificial construct in which the P88L mutation was introduced was created to examine its effects on γ-secretase cleavage. RESULTS Two novel variants in TMD-1 (P88L and V89L) were identified in affected probands. The neuropathological findings of AD were confirmed in the V89L mutation. Both patients presented around age 40 with early short-term memory deficits followed by seizures and corticospinal tract signs. The P88L mutation additionally featured early myoclonus followed by Parkinsonism. The causal role of the P88L mutation is supported by demonstration that this mutation dramatically increased Aβ42 and decreased APP and Notch intracellular domain production in vitro. CONCLUSION Changes in a single amino acid in codons 88 and 89 of TMD-1 can result in young-onset AD. The TMD-1 of PS1 is a region important for the γ-secretase cleavage of Aβ.

[1]  Nick C Fox,et al.  Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer’s disease: a case series , 2016, The Lancet Neurology.

[2]  Adrian Danek,et al.  Neurological manifestations of autosomal dominant familial Alzheimer’s disease: a comparison of the published literature with the Dominantly Inherited Alzheimer Network observational study (DIAN-OBS) , 2016, The Lancet Neurology.

[3]  E. Futai,et al.  Suppressor Mutations for Presenilin 1 Familial Alzheimer Disease Mutants Modulate γ-Secretase Activities* , 2015, The Journal of Biological Chemistry.

[4]  Charles DeCarli,et al.  Existing Pittsburgh Compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. , 2015, Brain : a journal of neurology.

[5]  T. Tomita Molecular mechanism of intramembrane proteolysis by γ-secretase. , 2014, Journal of biochemistry.

[6]  Takeshi Iwatsubo,et al.  Allosteric regulation of γ-secretase activity by a phenylimidazole-type γ-secretase modulator , 2014, Proceedings of the National Academy of Sciences.

[7]  B. Strooper,et al.  Signature Amyloid beta Profiles Are Produced by Different gamma-Secretase Complexes , 2014 .

[8]  T. Iwatsubo,et al.  Binding of longer Aβ to transmembrane domain 1 of presenilin 1 impacts on Aβ42 generation , 2014, Molecular Neurodegeneration.

[9]  B. de Strooper,et al.  Signature Amyloid β Profiles Are Produced by Different γ-Secretase Complexes* , 2013, The Journal of Biological Chemistry.

[10]  B. de Strooper,et al.  The mechanism of γ-Secretase dysfunction in familial Alzheimer disease , 2012, The EMBO journal.

[11]  J. Ringman,et al.  Comparison of clinical characteristics between familial and non-familial early onset Alzheimer’s disease , 2012, Journal of Neurology.

[12]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[13]  A. Singleton,et al.  Genetic screening of Alzheimer's disease genes in Iberian and African samples yields novel mutations in presenilins and APP , 2010, Neurobiology of Aging.

[14]  M. Rossor,et al.  Correlating familial Alzheimer's disease gene mutations with clinical phenotype. , 2010, Biomarkers in medicine.

[15]  I. McKeith II.3 Dementia with Lewy bodies , 2006 .

[16]  T. Iwatsubo,et al.  Solid-phase synthesis of photoaffinity probes: highly efficient incorporation of biotin-tag and cross-linking groups. , 2003, Chemical communications.

[17]  B. Ghetti,et al.  Presenilin-1 mutations of leucine 166 equally affect the generation of the Notch and APP intracellular domains independent of their effect on Aβ42 production , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Huaxi Xu,et al.  Presenilin 1 Is Required for Maturation and Cell Surface Accumulation of Nicastrin* , 2002, The Journal of Biological Chemistry.

[19]  R. Blesa,et al.  A novel mutation (V89L) in the presenilin 1 gene in a family with early onset Alzheimer's disease and marked behavioural disturbances , 2002, Journal of neurology, neurosurgery, and psychiatry.

[20]  F. D. Miller,et al.  Functional gamma‐secretase inhibitors reduce beta‐amyloid peptide levels in brain , 2000, Journal of neurochemistry.

[21]  S. Greenberg,et al.  Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy. , 1997, Stroke.

[22]  Nick C Fox,et al.  Clinicopathological features of familial Alzheimer's disease associated with the M139V mutation in the presenilin 1 gene. Pedigree but not mutation specific age at onset provides evidence for a further genetic factor. , 1997, Brain : a journal of neurology.

[23]  Charles Duyckaerts,et al.  National Institute on Aging–Alzheimer’s Association guidelines for the neuropathologic assessment of Alzheimer’s disease: a practical approach , 2011, Acta Neuropathologica.